Novozymes A/S (OTCMKTS:NVZMY) Short Interest Up 1,727.7% in August

Posted by Francis Steltz on Sep 12th, 2026

Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) was the target of a significant growth in short interest in the month of August. As of August 31st, there was short interest totaling 34,196 shares, a growth of 1,727.7% from the August 15th total of 1,871 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily volume of 46,883 shares, the days-to-cover ratio is currently 0.7 days.

Institutional Investors Weigh In On Novozymes A/S

A hedge fund recently raised its stake in Novozymes A/S stock. Elefante Mark B boosted its holdings in Novozymes A/S (OTCMKTS:NVZMY – Free Report) by 73.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,900 shares of the biotechnology company’s stock after acquiring an additional 2,500 shares during the quarter. Elefante Mark B’s holdings in Novozymes A/S were worth $371,000 at the end of the most recent quarter. 0.03% of the stock is currently owned by institutional investors and hedge funds.

Novozymes A/S Stock Up 0.5%

Shares of NVZMY traded up $0.35 during trading hours on Friday, reaching $66.24. The stock had a trading volume of 18,932 shares, compared to its average volume of 25,553. Novozymes A/S has a 12 month low of $49.90 and a 12 month high of $75.27. The firm has a 50-day simple moving average of $66.33 and a 200 day simple moving average of $61.51. The company has a current ratio of 1.67, a quick ratio of 1.03 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $27.46 billion, a price-to-earnings ratio of 41.92, a P/E/G ratio of 2.90 and a beta of 0.93.

Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) last announced its quarterly earnings results on Thursday, August 20th. The biotechnology company reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.16). Novozymes A/S had a net margin of 14.70% and a return on equity of 6.60%. The business had revenue of $1.30 billion for the quarter, compared to the consensus estimate of $1.27 billion. Equities research analysts predict that Novozymes A/S will post 2.47 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised shares of Novozymes A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, June 8th. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy”.

Check Out Our Latest Analysis on NVZMY

Novozymes A/S Company Profile

(Get Free Report)

Novozymes A/S was a Danish biotechnology company that developed and commercialized enzymes, microorganisms and other biological solutions for industrial and consumer applications. Its technologies were designed to help customers improve production efficiency, reduce resource use and develop more sustainable products and processes.

The company supplied biological products and related solutions to a range of industries, including food and beverages, household care, agriculture, animal health, bioenergy and industrial manufacturing.